Болезнь, вызываемая вирусом Эбола: от теории к практике


https://doi.org/10.22625/2072-6732-2015-7-1-5-17

Полный текст:


Аннотация

В представленной статье обобщены результаты последних эпидемиологических, клинических, вирусологических исследований, направленных на изучение инфекции, вызванной вирусом Эбола. Особое внимание уделено организационным мероприятиям по борьбе с данным заболеванием. Изложены принципы медицинской помощи больным геморрагической лихорадкой Эбола. Подробно описано участие медицинской службы МО РФ в развертывании и организации работы военно-полевого инфекционного госпиталя на 100 коек в республике Гвинея. 


Об авторах

К. В. Жданов
Военно-медицинская академия имени С.М. Кирова, Санкт-Петербург, Россия
Россия

начальник кафедры инфекционных болезней Военно-медицинской академии им. С.М. Кирова, д.м.н. профессор; тел.: 8(812)542-92-14



И. В. Холиков
Главное Военно-медицинское управление, Москва, Россия
Россия

начальник департамента по международным отношениям Главного Военно-медицинского управления, д.ю.н.; тел.: 8(495)696 -98-67



Список литературы

1. Международные медико-санитарные правила (2005) / Второе издание. – Женева: ВОЗ, 2008. – 82 с. [cited 09.Jan.2015]. Available from: http://whqlibdoc.who.int/public atitions/2008/9789244580417_rus.pdf .

2. Editorial. Ebola: what lessons for the International Health Regulations? // The Lancet. – 2014. – Vol. 384,N 9951. – P. 1321.

3. Sanchez A. [et al.]. Filoviridae: Marburg and Ebola viruses. In: Knipe D.M., Howley P.M., eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins – 2006. – P. 1409-1448.

4. Geisbert T.W. Marburg and Ebola Hemorrhagic Fever (Filoviruses). In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Eighth Edition. – Philadelphia: Elsevier. – 2015. – P. 1995-1999.

5. Centers for Disease Control and Prevention. Bioterrorism agents/diseases. [cited 20 March 2010]. Available from: http:// www.bt.cdc.gov/agent/agentlist-category.asp#a.

6. Ebola haemorrhagic fever in Sudan, 1976. Report of an International Commission // Bull. of WHO. – 1978. – Vol. 56, N 2. – P. 247-270.

7. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. // Bull. of WHO. – 1978. – Vol. 56, N 2. – P.271-293.

8. Lefebvre A. Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data. / A. Lefebvre, C. Fiet, C. Belpois-Duchamp et al. // Médecine et maladies infectieuses. – 2014. – Vol. 44. – P. 412-416.

9. Платонов А.Е. Эбола, 2014 г. Эпидемиологические и социальные аспекты / А.Е. Платонов, О.В.Платонова, В.В. Малеев // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2014, No5. – С. 34-49.

10. WHO Ebola Response Team. Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections. N. Engl. J. Med., 2014; 371 (16): 1481-1495.

11. WHO: Ebola Response Roadmap Situation Report. [cited 07 Jan 2015]. Available from: http://apps.who.int/ebolaweb/sitreps/20150114/20150114.pdf.

12. Kuhn J.H. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations / J.H. Kuhn, S. Becker, H. Ebihara et al. // Archives of Virology. – 2010. – Vol. 155, N 12. – P. 2083–2103.

13. Taylor D. Filoviruses are ancient and integrated into mammalian genomes / D. Taylor, R. Leach, J. Bruenn // BMC Evolutionary Biology, 2010. – Vol. 10. – P. 193.

14. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation. INTERIM vers. 1.2. WHO., Geneva, Switzerland, 2014; 123 p. [cited 09 Jan 2015]. Available from: http://www.who.int/csr/disease/ebola/manual_EVD/ en/

15. Camacho A. Potential for large outbreaks of Ebola virus disease / A.Camacho, A.J. Kucharski, S. Funk et al. // Epidemics. – 2014. – Vol. 9. – P. 70-78.

16. Georges-Courbot M.C. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon / M.C. Georges-Courbot, A. Sanchez, C.Y. Lu et al. // Emerg Infect Dis. – 1997. – Vol. 3, N1. – P. 59-62.

17. Leroy E.M. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007 / E.M. Leroy, A. Epelboin, V. Mondonge et al.// Vector Borne Zoonotic Dis. – 2009. – Vol. 9, N6. – P. 723-728.

18. MacIntyre C.R. Respiratory protection for healthcare workers treating Ebola virus disease (EVD): Are facemasks sufficient to meet occupational health and safety obligations? / C.R. MacIntyre, G.A. Richards, P.M. Davidson // International Journal of Nursing Studies. – 2014. – Vol. 51. – P. 1421–1426.

19. Personal Protective Equipment in the Context of Filovirus Disease Outbreak Response. Rapid advice guideline. October 2014. – WHO., Geneva, Switzerland, 2014; – 10 p. [cited 09 Jan 2015]. Available from: http://apps. who.int/iris/bitstream/ 10665/137410/1/WHO_EVD_Guidance_PPE_14.1_ eng.pdf )

20. World Health Organization (WHO), 2014b. Unprecedented Number of Medical Staff Infected with Ebola. [cited 09 Jan 2015]. Available from: http://www.who.int/ mediacentre/ news/ebola/25-august-2014/en

21. Gibbs N., edt. Person of the Year. The Choice. Time, 2014: Vol. 168 (26). [cited 05 Jan 2015]. Available from: http:// content.time.com/time/covers/0,16641,20061225,00.html.

22. Carette J.E. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1/ J.E. Carette, M. Raaben, A.C. Wong et al. // Nature. – 2011. – Vol. 477,N 7364. – P. 340– 343.

23. Kondratowicz A.S. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus / A.S. Kondratowicz, N.J. Lennemann, P.L. Sinn et al. // Proc. Natl. Acad. Sci. U.S.A. – 2011. – Vol. 108,N20. – P. 8426-8431.

24. Flemming A. Achilles heel of Ebola viral entry / A. Flemming // Nat. Rev. Drug. Discov. – 2011. – Vol. 10,N1. – P. 731-736.

25. Bray M. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus / M. Bray, S. Hatfill, L. Hensley et. al. // J Comp Pathol. – 2001. – Vol. 125. – P. 243-253.

26. Geisbert T.W. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection / T.W. Geisbert, L.E. Hensley, T. Larsen et al. // Am J Pathol. – 2003. – Vol. 163, N6. – P. 2347-2370.

27. Geisbert T.W. Pathogenesis of Ebola haemorrhagic fever in primate models: evidence that haemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells / T.W. Geisbert, H.A. Young, P.B. Jahrling et al. // Am J Pathol. – 2003. – Vol. 163,N6. – P. 2371-2382.

28. Mahanty S. Pathogenesis of filoviral haemorrhagic fevers / S. Mahanty, M. Bray // The Lancet Infectious Diseases. – 2004. – Vol. 4,N8. – P. 487-498.

29. Yang Z.Y. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury / Z.Y. Yang, H.J. Duckers, N.J. Sullivan et al. // Nat Med. – 2000. – 6,N8. – P. 886-889.

30. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans / S.R. Zaki, C.S. Goldsmith // Curr Top Microbiol Immunol. – 1999. – Vol. 235. – P. 97-116.

31. Sanchez A. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels / A. Sanchez, M. Lukwiya, D. Bausch et al. // J Virol. – 2004. – Vol. 78,N19. – P. 10370-10377.

32. Ebihara H. Molecular determinants of Ebola virus virulence in mice / H. Ebihara, A. Takada, D. Kobasa et al. // PLoS Pathog. – 2006. – 2,N7. – P. e73.

33. Feldmann H. Ebola haemorrhagic fever / H. Feldmann, T.W. Geisbert // Lancet. – 2011. – Vol. 377,N 9768. – P. 849862.

34. Bellan S.E. Ebola control: effect of asymptomatic infection and acquired immunity/ S.E. Bellan, J.R.C. Pulliam, J. Dushoff et. al. // Lancet. – 2014. – Vol. 384,N 9953. – P. 1499-1500.

35. Huggins J.W. Prospects for treatment of viral haemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug / J.W.Huggins // Rev Infect Dis. – 1989. – 11 (suppl 4) . – P. S750-S761.

36. Ignatyev G. Experimental study on the possibility of treatment of some haemorrhagic fevers / G. Ignatyev, A.Steinkasserer, M. Streltsova et. al. // J Biotechnol. – 2000. – Vol. 83. – P. 67-76.

37. Жданов К.В. Терапия геморрагической лихорадки Эбола / К.В. Жданов, А.В. Щеголев, А.Н. Коваленко // Воен.-мед. журн. – 2015. – Т. 336, No 3. – In press.

38. Ethical considerations for use of unregistered interventions for Ebola virus disease. Report of an advisory panel to WHO. (WHO/HIS/KER/GHE.14.1.) Geneva: World Health Organization, 2014. [cited 09 Jan 2015]. Available from: http:// who.int/csr/resources/publications/ebola/ethical-considerations/en/.

39. Potential Ebola therapies and vaccines. WHO/EVD/ HIS/EMP/14.1. – Geneva: World Health Organization, 5 November 2014. – 36 p.

40. Борисевич И.В.. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. / И.В. Борисевич, В.П. Краснянский, В.В. Михайлов и др. // Вопр. вирусол. 1995. Т. 40,No6. С. 194–197.

41. Dye J.M. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease / J.M. Dye, A.S. Herbert, A.I.Kuehne et. al. // Proc Natl Acad Sci USA. – 2012. – Vol. 109. – P.5034–5039.

42. Патент No 213038, Российская федерация RU 20.05.1999. Препарат, содержащий иммуноглобулин против лихорадки Эбола, из сыворотки крови лошадей, жидкий (Иммуноглобулин Эбола) / Михайлов В.В., Борисевич И.В., Тиманькова Г.Д., и др. Available from: http://www.vpk-news. ru/print.asp?pr_sign=archive.2004.33.articles.rostrum_01.

43. Smith L.M. Interferon-β Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg / L.M. Smith, L.E. Hensley, T.W. Geisbert et al. // Journal of Infectious Diseases. – 2013. – Vol. 208. – P. 310–318.

44. Qiu X. Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs / X. Qiu, G. Wong, L. Fernando et. al. // J. Virol. . – 2013. – Vol. 87,N13. – P. 7754 – 7757.

45. Qiu X. Successful treatment of Ebola virus–infected cynomolgus macaques with monoclonal antibodies / X. Qiu, J. Audet, G. Wong et al. // Sci. Transl. Med. – 2013. – Vol. 4,N 138. – P. 138ra81.

46. Pettitt J. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail / J. Pettitt, L. Zeitlin, H. Kim do et al. // Sci. Transl. Med. – 2013. – Vol. 5, N199. – P. 199ra113.

47. Mohammadi D. First trials for Ebola treatment announced / D. Mohammadi // The Lancet. – 2014. – Vol. 384, N 9957. – P. 1833.

48. O’Brien L.M. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse / L.M. O’Brien, M.G. Stokes, S.G. Lonsdale et al. // Virology. – 2014. – Vol. 452, N 453. – P. 324–333.

49. Report of the Joint review meeting facilitated by the World Health Organization for the GSK ChAd3 Ebola Vaccine Clinical Trials Application / WHO, 15-16 December 2014. [cited 16 Dec 2014]. Available from: http://www.who.int/medicines/ ebola-treatment/meetings/gsk-vaccine-trials.pdf?ua=1.

50. WHO Ebola R&D Effort – vaccines, therapies, diagnostics [cited 30 Jan 2014]. Available from: http://www.who.int/ medicines/ebola-treatment/ebola_r_d_effort/en/.

51. В России разрабатывают три вакцины от лихорадки Эбола. [cited 11 Oct 2014]. Available from: http://www. newsru.com/russia/11oct2014/ebola.html.

52. Фисун А.Я. Болезнь, вызванная вирусом Эбола: клинико-диагностические аспекты и организация лечебнодиагностических мероприятий / А.Я. Фисун, К.В. Жданов, С.М. Захаренко и др. // Воен.-мед. Журн. – 2014. – Т. 335, No 11. – С. 4–11.


Дополнительные файлы

Для цитирования: Жданов К.В., Холиков И.В. Болезнь, вызываемая вирусом Эбола: от теории к практике. Журнал инфектологии. 2015;7(1):5-17. https://doi.org/10.22625/2072-6732-2015-7-1-5-17

For citation: Zhdanov K.V., Holikov I.V. Disease caused by the Ebola virus: from theory to practice. Journal Infectology. 2015;7(1):5-17. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-1-5-17

Просмотров: 384

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2072-6732 (Print)
ISSN 2499-9865 (Online)